Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals

Rare disease drug developer Insmed on Monday revealed data from a mid-stage trial of its daily pill for adults with non-cystic fibrosis bronchiectasis, a severe chronic pulmonary disorder with no FDA-approved therapies.